Erlangen, Germany, November 6, 2024 / PRNewswire / - Siemens Healthineers today released its financial performance report for the fourth quarter of the 2024 fiscal year and the full fiscal year ending September 30, 2024.

Fiscal year 2024 - Achieving revenue growth and earnings per share targets

• The equipment order delivery ratio reached a very good 1.11; the backlog of orders continues to increase
• Although the Chinese market environment experienced complex changes in the 2024 fiscal year, the global comparable revenue still increased by 4.7% for the full year; excluding the previous year's discontinued business of rapid antigen testing for the novel coronavirus, comparable revenue grew by 5.2%
• The adjusted EBITDA margin is 15.7%, which is 0.7 percentage points higher than the previous fiscal year; the adjusted EBITDA increased to 3.5 billion euros.
• The adjusted basic earnings per share reached 2.23 euros.
• The free cash flow is approximately 2.1 billion euros, significantly higher than the previous fiscal year.
• The proposed dividend is 0.95 euros per share, unchanged from last year.

Q4 FY2024 - Revenue from Imaging, Varian, and Clinical Therapy businesses all experienced significant growth.

• Equipment order shipment ratio reached a very good 1.12.
• Comparable revenue growth of 5.6%; excluding the rapid antigen testing business for COVID-19 that ended in the same quarter of the previous year, comparable revenue growth was 6.5%.
• Comparable revenue growth for the Imaging business was 7.7%, with an impressive adjusted EBIT margin of 24.2%.
• After the end of the COVID-19 antigen rapid testing business, the laboratory diagnostic business saw a comparable revenue growth of 0.6%; if the COVID-19 antigen rapid testing business is included, the comparable revenue declines by 3.8%; due to the impact of factors related to the previous financial reporting period, the adjusted EBITDA margin is 4.7%.
• Building on its strong performance in the same period last year, the Varian business achieved a comparable revenue growth of 10.5%; the adjusted EBITDA margin is 17.1%.
• The clinical treatment business experienced a comparable revenue growth of 6.8%; the adjusted EBITDA margin reached an outstanding 20.0%.
• The overall adjusted EBITDA margin after adjustments is 17.7%, higher than the same period last year.
• Free cash flow reached 1.2 billion euros, more than doubled compared to the same period last year.
• Adjusted basic earnings per share were 0.67 euros.

Outlook for the 2025 fiscal year

Siemens Medical expects that comparable revenue for the 2025 fiscal year will increase by 5% to 6% from the 2024 fiscal year, with adjusted basic earnings per share between 2.35 and 2.50 euros.

Bernd Montag, CEO of Siemens Healthineers: "Although the demand in the Chinese market slowed down in the fourth quarter of the fiscal year, Siemens Healthineers globally achieved outstanding performance during this quarter, successfully meeting the 2024 fiscal year targets. This fully demonstrates the company's strong capabilities, also credited to the contributions of all team members. In the 2025 fiscal year, we will continue to maintain this momentum."

About Siemens Healthineers

Striving for innovation, for every life. Siemens Healthineers is a global leader in medical devices, solutions, and services, with operations in over 180 countries and regions, and direct business activities in more than 70 countries and regions. Siemens Healthineers consists of Siemens Healthineers AG (Frankfurt Stock Exchange code: SHL) and its subsidiaries. As a leading medical technology company, Siemens Healthineers is dedicated to improving access to high-quality medical resources and tackling life-threatening diseases. Siemens Healthineers' business spans medical imaging, in-vitro diagnostics, cancer treatment, minimally invasive therapies, enhanced by digital technology and artificial intelligence in each sector. As of the 2023 fiscal year (ends on September 30, 2023), Siemens Healthineers has approximately 71,000 employees worldwide, with revenue of around 21.7 billion euros. For more information, please visit